{"id":30061,"date":"2024-10-15T18:54:46","date_gmt":"2024-10-15T13:24:46","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30061"},"modified":"2024-10-15T18:54:47","modified_gmt":"2024-10-15T13:24:47","slug":"pharma-news-for-astellas-gsk-astrazeneca","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astellas-gsk-astrazeneca","title":{"rendered":"Astellas &amp; AviadoBio\u2019s Exclusive Deal for AVB-101; GSK&#8217;s Depemokimab Shows Positive Results for Nasal Polyps; Lilly&#8217;s Mirikizumab Outperforms Ustekinumab in Crohn&#8217;s Study; TREMFYA Delivers Strong Results in Crohn\u2019s &amp; Colitis; ENHERTU Approved in China for HER2-Mutant NSCLC."},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69de6f703c856\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69de6f703c856\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astellas-gsk-astrazeneca\/#Astellas_AviadoBio_Sign_Exclusive_Deal_for_Gene_Therapy_AVB-101_in_Frontotemporal_Dementia\" >Astellas &amp; AviadoBio Sign Exclusive Deal for Gene Therapy AVB-101 in Frontotemporal Dementia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astellas-gsk-astrazeneca\/#GSKs_Depemokimab_Shows_Positive_Phase_III_Results_for_Chronic_Rhinosinusitis_with_Nasal_Polyps\" >GSK&#8217;s Depemokimab Shows Positive Phase III Results for Chronic Rhinosinusitis with Nasal Polyps<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astellas-gsk-astrazeneca\/#Lillys_Mirikizumab_Outperforms_Ustekinumab_in_One-Year_Phase_III_Crohns_Study\" >Lilly&#8217;s Mirikizumab Outperforms Ustekinumab in One-Year Phase III Crohn&#8217;s Study<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astellas-gsk-astrazeneca\/#TREMFYA_Delivers_Strong_Results_in_Biologic-Naive_and_Refractory_Crohns_Ulcerative_Colitis_Patients\" >TREMFYA Delivers Strong Results in Biologic-Na\u00efve and Refractory Crohn\u2019s &amp; Ulcerative Colitis Patients<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astellas-gsk-astrazeneca\/#ENHERTU_Approved_in_China_as_First_HER2-Targeted_Treatment_for_HER2-Mutant_NSCLC\" >ENHERTU Approved in China as First HER2-Targeted Treatment for HER2-Mutant NSCLC<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-astellas-amp-aviadobio-sign-exclusive-deal-for-gene-therapy-avb-101-in-frontotemporal-dementia\"><span class=\"ez-toc-section\" id=\"Astellas_AviadoBio_Sign_Exclusive_Deal_for_Gene_Therapy_AVB-101_in_Frontotemporal_Dementia\"><\/span>Astellas &amp; AviadoBio Sign Exclusive Deal for Gene Therapy AVB-101 in Frontotemporal Dementia<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>AviadoBio Ltd. and Astellas Pharma Inc. have announced a strategic partnership under an exclusive option and license agreement for AVB-101, an investigational AAV-based gene therapy currently in Phase I\/II development for <a href=\"https:\/\/www.delveinsight.com\/report-store\/frontotemporal-dementia-market\">patients with frontotemporal dementia<\/a> caused by progranulin mutations (FTD-GRN). Frontotemporal dementia is a rare, aggressive form of early-onset dementia that typically leads to death within three to 13 years after diagnosis. It often results in a rapid decline in cognitive and executive functions, behavioral changes, language loss, apathy, and mobility challenges. Despite its prevalence in people under 65, frontotemporal dementia is frequently underrecognized and misdiagnosed.<\/p>\n\n\n\n<p>Through the agreement, Astellas gains an option for a worldwide exclusive license to develop and commercialize AVB-101 for FTD-GRN and other potential indications. Astellas will invest $20 million in equity and make upfront payments of up to $30 million. If Astellas chooses to exercise the option, AviadoBio could receive up to $2.18 billion in license fees and milestone payments, plus additional royalties.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;We are thrilled about the potential of this collaboration,&#8221; said <\/em><strong><em>Lisa Deschamps<\/em><\/strong><em>, CEO of AviadoBio. &#8220;As we complete dosing of the first cohort of patients in our Phase I\/II ASPIRE-FTD trial of AVB-101, this partnership combines our gene therapy expertise with Astellas\u2019 global capabilities. Together, we aim to deliver this much-needed therapy to families around the world who are grappling with the severe impact of FTD-GRN and other neurological diseases.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>Adam Pearson<\/em><\/strong><em>, Chief Strategy Officer of Astellas, added, &#8220;We are excited to work with AviadoBio to expand our gene therapy pipeline. AVB-101 represents a novel approach to treating FTD-GRN and aligns with our focus on genetic regulation as a key strategy. This agreement underscores our commitment to providing innovative solutions for patients living with devastating neurodegenerative diseases.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-gsk-s-depemokimab-shows-positive-phase-iii-results-for-chronic-rhinosinusitis-with-nasal-polyps\"><span class=\"ez-toc-section\" id=\"GSKs_Depemokimab_Shows_Positive_Phase_III_Results_for_Chronic_Rhinosinusitis_with_Nasal_Polyps\"><\/span>GSK&#8217;s Depemokimab Shows Positive Phase III Results for Chronic Rhinosinusitis with Nasal Polyps<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>GSK plc has announced positive results from the phase III ANCHOR-1 and ANCHOR-2 trials, evaluating the efficacy and safety of <strong>depemokimab<\/strong> in <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-rhinosinusitis-with-nasal-polyps-market\">adults with chronic rhinosinusitis with nasal polyps (CRSwNP)<\/a>. Both trials met their co-primary endpoints, showing a significant reduction in total nasal polyp score and nasal obstruction after 52 weeks of treatment. The incidence of treatment-emergent adverse events was comparable between depemokimab and placebo groups, with full results expected to be presented at an upcoming scientific congress.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>Kaivan Khavandi<\/em><\/strong><em>, SVP of Global Respiratory\/Immunology R&amp;D at GSK, highlighted the significance of the findings: &#8220;Millions suffer from uncontrolled CRSwNP, often facing high corticosteroid use and recurrent nasal polyps post-surgery. The ANCHOR studies show depemokimab\u2019s potential to provide targeted and sustained suppression of inflammation, offering a new therapeutic option for these patients.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Depemokimab, the first ultra-long-acting biologic of its kind, targets <strong>interleukin-5 (IL-5)<\/strong>, a key protein in type 2 inflammation. With an extended half-life, depemokimab has the potential to be administered once every six months, offering long-lasting relief for CRSwNP patients, while reducing the need for frequent clinic visits.<\/p>\n\n\n\n<p>The results from ANCHOR-1 and ANCHOR-2, combined with data from the SWIFT trials in severe asthma, will be used for global regulatory filings. If approved, depemokimab could significantly advance the treatment landscape for CRSwNP, benefiting patients who currently face inadequate or suboptimal treatment options.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lilly-s-mirikizumab-outperforms-ustekinumab-in-one-year-phase-iii-crohn-s-study\"><span class=\"ez-toc-section\" id=\"Lillys_Mirikizumab_Outperforms_Ustekinumab_in_One-Year_Phase_III_Crohns_Study\"><\/span>Lilly&#8217;s Mirikizumab Outperforms Ustekinumab in One-Year Phase III Crohn&#8217;s Study<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Eli Lilly and Company has announced encouraging results from the VIVID-1 Phase III trial, which evaluated <strong>mirikizumab<\/strong> in <a href=\"https:\/\/www.delveinsight.com\/report-store\/crohns-disease-cd-market\">patients with moderately to severely active <strong>Crohn&#8217;s disease<\/strong><\/a>. Data revealed that more patients treated with mirikizumab achieved a <strong>histologic response<\/strong> at Week 52 compared to those treated with <strong>ustekinumab<\/strong>, regardless of prior biologic experience. This study marks the first Phase III trial for any approved or investigational treatment in Crohn\u2019s disease to evaluate histologic and endoscopic outcomes systematically across five bowel segments, as presented at the <strong>United European Gastroenterology (UEG) Week<\/strong> in Vienna, Austria.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Mirikizumab, an <\/em><strong><em>IL23p19 antagonist<\/em><\/strong><em>, selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. This mechanism targets the underlying <\/em><strong><em>inflammation<\/em><\/strong><em> driving <\/em><strong><em>Crohn&#8217;s disease<\/em><\/strong><em>, a chronic inflammatory bowel disease that can cause progressive damage to the intestines and impair a patient&#8217;s quality of life. &#8220;These histologic data build on the growing evidence for mirikizumab, which may provide a greater depth of mucosal healing for those living with this chronic, progressive disease,&#8221; said <\/em><strong><em>Fernando Magro, M.D.<\/em><\/strong><em>, head of clinical pharmacology at University Hospital S\u00e3o Jo\u00e3o.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Results from the trial showed that 58.2% of patients treated with mirikizumab achieved a <strong>histologic response<\/strong> by Week 52, compared to 48.8% for ustekinumab. In patients with previous biologic failure, the response rate was similarly higher for mirikizumab (56.5% vs. 41.3%). Notably, the study also assessed <strong>endoscopic-histologic response<\/strong>, showing mirikizumab&#8217;s potential to address deep tissue healing. The safety profile of mirikizumab was consistent with previous studies in ulcerative colitis, with common adverse events including COVID-19, anemia, and upper respiratory infections.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>Mark Genovese, M.D.<\/em><\/strong><em>, Senior VP of Lilly Immunology Development, highlighted the importance of this breakthrough: &#8220;By aligning histologic outcomes with ECCO&#8217;s recent position statement, we\u2019re setting a new standard in the evaluation of Crohn\u2019s disease treatments.&#8221; Lilly has submitted global regulatory applications for mirikizumab and continues its research into the drug&#8217;s long-term safety and efficacy, including studies in pediatric patients and further trials in <\/em><strong><em>ulcerative colitis<\/em><\/strong><em>, marketed under the name <\/em><strong><em>OMVOH<\/em><\/strong><em>.<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-tremfya-delivers-strong-results-in-biologic-naive-and-refractory-crohn-s-amp-ulcerative-colitis-patients\"><span class=\"ez-toc-section\" id=\"TREMFYA_Delivers_Strong_Results_in_Biologic-Naive_and_Refractory_Crohns_Ulcerative_Colitis_Patients\"><\/span>TREMFYA Delivers Strong Results in Biologic-Na\u00efve and Refractory Crohn\u2019s &amp; Ulcerative Colitis Patients<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Johnson &amp; Johnson has shared promising results from their ongoing clinical trials on <strong>TREMFYA (guselkumab)<\/strong> for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/crohns-disease-cd-market\"><strong>Crohn\u2019s disease<\/strong><\/a><strong> <\/strong>and <a href=\"https:\/\/www.delveinsight.com\/report-store\/ulcerative-colitis-uc-market\"><strong>ulcerative colitis<\/strong><\/a>. Data presented at the <strong>United European Gastroenterology (UEG) Week 2024<\/strong> show that TREMFYA\u00ae demonstrated high rates of <strong>endoscopic remission<\/strong> in both biologic-na\u00efve and biologic-refractory patients, including those who had not responded to <strong>JAK inhibitors<\/strong>. These findings, drawn from the Phase III <strong>GALAXI 2 &amp; 3 studies<\/strong> in CD and the <strong>QUASAR maintenance study<\/strong> in ulcerative colitis, are crucial as they indicate significant potential for TREMFYA to be a differentiated treatment option, especially for patients who have previously failed biologic therapies.<\/p>\n\n\n\n<p>In biologic-na\u00efve patients with Crohn\u2019s Disease, <strong>TREMFYA<\/strong> showed superior endoscopic remission rates compared to <strong>ustekinumab<\/strong> in the pooled Phase III GALAXI 2 &amp; 3 dataset. At Week 48, 44% of patients receiving TREMFYA 100 mg every eight weeks (q8w) achieved endoscopic remission, while the 200 mg every four weeks (q4w) dose saw a slightly higher rate of 46.1%. This is compared to ustekinumab, which showed a 29.8% remission rate in the same population. In the QUASAR study, similar improvements were seen in <strong>biologic\/JAK inhibitor-na\u00efve patients<\/strong> with ulcerative colitis, where endoscopic remission was achieved in 38.1% of patients on the 100 mg q8w dose, and 41.7% on the 200 mg q4w dose, compared to 20.4% in the placebo group.<\/p>\n\n\n\n<p>The studies also assessed the impact of TREMFYA\u00ae on biologic-refractory patients with Crohn\u2019s Disease and JAK inhibitor-refractory patients with ulcerative colitis. In the biologic-refractory Crohn\u2019s Disease group, 28.1% of patients treated with TREMFYA 100 mg q8w and 28.6% with the 200 mg q4w dose achieved <strong>endoscopic remission<\/strong>, compared to 20.5% with ustekinumab. For ulcerative colitis patients refractory to biologics or JAK inhibitors, the QUASAR study showed endoscopic remission rates of 31.2% in those on 100 mg q8w and 23.9% in those on 200 mg q4w, compared to just 8% in the placebo group, marking a significant improvement in this difficult-to-treat population.<\/p>\n\n\n\n<p><strong>The U.S. FDA recently approved TREMFYA\u00ae<\/strong> in September 2024 for treating adults with moderately to severely active ulcerative colitis, and its application for Crohn\u2019s Disease is currently under review. Regulatory submissions are also underway in Europe for both indications. These results not only reinforce the well-established safety profile of TREMFYA but also solidify its role as a key player in treating <strong>inflammatory bowel diseases<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-enhertu-approved-in-china-as-first-her2-targeted-treatment-for-her2-mutant-nsclc\"><span class=\"ez-toc-section\" id=\"ENHERTU_Approved_in_China_as_First_HER2-Targeted_Treatment_for_HER2-Mutant_NSCLC\"><\/span>ENHERTU Approved in China as First HER2-Targeted Treatment for HER2-Mutant NSCLC<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>AstraZeneca and Daiichi Sankyo have achieved a significant milestone with <strong>ENHERTU (trastuzumab deruxtecan)<\/strong> receiving conditional approval in China for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\">treatment of <strong>HER2-mutant non-small cell lung cancer (NSCLC)<\/strong><\/a>. This approval marks an important breakthrough for patients with <strong>unresectable, locally advanced, or metastatic NSCLC<\/strong> who have received prior systemic therapy. The approval by China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> is based on positive results from the <strong>DESTINY-Lung02<\/strong> and <strong>DESTINY-Lung05<\/strong> Phase II trials, and full approval will depend on further confirmatory trial results that demonstrate clinical benefit.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Lung cancer is a significant public health concern in China, with over a million new cases diagnosed annually, accounting for more than 40% of the global lung cancer population. Among these, <\/em><strong><em>2% to 4% of NSCLC patients<\/em><\/strong><em> have <\/em><strong><em>HER2 mutations<\/em><\/strong><em>, which historically had limited treatment options. According to <\/em><strong><em>Ying Cheng, MD, PhD<\/em><\/strong><em>, Director of Jilin Lung Cancer Centre, the approval of ENHERTU is a critical step forward, as it provides a much-needed targeted therapy for patients with this aggressive subtype of lung cancer. <\/em><strong><em>Dave Fredrickson<\/em><\/strong><em>, Executive Vice President of AstraZeneca\u2019s Oncology Business Unit, emphasized that this is the first <\/em><strong><em>HER2-directed<\/em><\/strong><em> therapy approved in China for HER2-mutant NSCLC, highlighting the importance of <\/em><strong><em>biomarker testing<\/em><\/strong><em> in treatment personalization.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The clinical data backing this approval comes from the <strong>DESTINY-Lung02<\/strong> trial, where ENHERTU showed a confirmed <strong>objective response rate (ORR)<\/strong> of 49% in patients from Japan, Korea, and Taiwan, with a <strong>median duration of response (DoR)<\/strong> of 16.8 months and a <strong>progression-free survival (PFS)<\/strong> of 9.9 months. Meanwhile, the <strong>DESTINY-Lung05<\/strong> trial in China revealed an even higher ORR of 58.3% in previously treated patients, showcasing ENHERTU&#8217;s consistent efficacy across different populations. These results are promising, providing hope for improved outcomes in patients with HER2-mutant NSCLC.<\/p>\n\n\n\n<p>ENHERTU is a <strong>HER2-directed antibody-drug conjugate (ADC)<\/strong> jointly developed by AstraZeneca and Daiichi Sankyo, and its approval in China for NSCLC follows its previous success in <strong>HER2-positive breast and gastric cancers<\/strong>. The drug is now approved in more than 45 countries, including the US, Japan, and across the EU. This fourth approval in China demonstrates the broad potential of ENHERTU across multiple tumor types, solidifying its place in oncology as a versatile and highly effective treatment for <strong>HER2-targetable cancers<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Astellas &amp; AviadoBio Sign Exclusive Deal for Gene Therapy AVB-101 in Frontotemporal Dementia AviadoBio Ltd. and Astellas Pharma Inc. have announced a strategic partnership under an exclusive option and license agreement for AVB-101, an investigational AAV-based gene therapy currently in Phase I\/II development for patients with frontotemporal dementia caused by progranulin mutations (FTD-GRN). Frontotemporal dementia [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":30062,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[22099,2077,204,704,16004,349,420,6733,1111,639,5789,16410],"industry":[17225],"therapeutic_areas":[17239,17245,17228,17243],"class_list":["post-30061","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-chronic-rhinosinusitis-with-nasal-polyposis","tag-crohns-disease","tag-delveinsight","tag-fda","tag-frontotemporal-dementia","tag-latest-pharma-news","tag-news","tag-non-small-cell-lung-cancer","tag-nsclc","tag-pharma-news","tag-recent-pharma-news","tag-ulcerative-colitis","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Astellas, GSK, AstraZeneca<\/title>\n<meta name=\"description\" content=\"Astellas-AviadoBio AVB-101 Deal, GSK&#039;s Depemokimab Success, Lilly&#039;s Mirikizumab Win, TREMFYA in Crohn&#039;s, ENHERTU China Approval.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astellas-gsk-astrazeneca\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Astellas, GSK, AstraZeneca\" \/>\n<meta property=\"og:description\" content=\"Astellas-AviadoBio AVB-101 Deal, GSK&#039;s Depemokimab Success, Lilly&#039;s Mirikizumab Win, TREMFYA in Crohn&#039;s, ENHERTU China Approval.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astellas-gsk-astrazeneca\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-15T13:24:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-15T13:24:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/15185425\/Pharma-news-for-astellas-gsk-astrazeneca.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Astellas, GSK, AstraZeneca","description":"Astellas-AviadoBio AVB-101 Deal, GSK's Depemokimab Success, Lilly's Mirikizumab Win, TREMFYA in Crohn's, ENHERTU China Approval.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astellas-gsk-astrazeneca","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Astellas, GSK, AstraZeneca","og_description":"Astellas-AviadoBio AVB-101 Deal, GSK's Depemokimab Success, Lilly's Mirikizumab Win, TREMFYA in Crohn's, ENHERTU China Approval.","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astellas-gsk-astrazeneca","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-10-15T13:24:46+00:00","article_modified_time":"2024-10-15T13:24:47+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/15185425\/Pharma-news-for-astellas-gsk-astrazeneca.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astellas-gsk-astrazeneca","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astellas-gsk-astrazeneca","name":"Pharma News | Astellas, GSK, AstraZeneca","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astellas-gsk-astrazeneca#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astellas-gsk-astrazeneca#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/15185425\/Pharma-news-for-astellas-gsk-astrazeneca.png","datePublished":"2024-10-15T13:24:46+00:00","dateModified":"2024-10-15T13:24:47+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Astellas-AviadoBio AVB-101 Deal, GSK's Depemokimab Success, Lilly's Mirikizumab Win, TREMFYA in Crohn's, ENHERTU China Approval.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astellas-gsk-astrazeneca"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-astellas-gsk-astrazeneca#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/15185425\/Pharma-news-for-astellas-gsk-astrazeneca.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/15185425\/Pharma-news-for-astellas-gsk-astrazeneca.png","width":772,"height":482,"caption":"Pharma-news-for-astellas-gsk-astrazeneca"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/15185425\/Pharma-news-for-astellas-gsk-astrazeneca-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">chronic rhinosinusitis with nasal polyposis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Crohn\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Frontotemporal dementia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NSCLC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ulcerative colitis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">chronic rhinosinusitis with nasal polyposis<\/span>","<span class=\"advgb-post-tax-term\">Crohn\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Frontotemporal dementia<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/span>","<span class=\"advgb-post-tax-term\">NSCLC<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Ulcerative colitis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Oct 15, 2024","modified":"Updated on Oct 15, 2024"},"absolute_dates_time":{"created":"Posted on Oct 15, 2024 6:54 pm","modified":"Updated on Oct 15, 2024 6:54 pm"},"featured_img_caption":"Pharma-news-for-astellas-gsk-astrazeneca \n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30061"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30061\/revisions"}],"predecessor-version":[{"id":30063,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30061\/revisions\/30063"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30062"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30061"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30061"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}